FDAnews
www.fdanews.com/articles/96811-kosan-rsquo-s-motilin-receptor-agonist-enters-phase-i-clinical-trial

Kosan’s Motilin Receptor Agonist Enters Phase I Clinical Trial

August 6, 2007

Kosan Biosciences announced that Pfizer has initiated a Phase I clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, for the treatment of gastroesophageal reflux disease and potentially other gastrointestinal (GI) disorders.

The Phase I clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects, Kosan said.

In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan’s motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million, according to the company.

The company added that in preclinical studies, PF-04548043 showed an improved safety profile relative to erythromycin and accelerated gastric emptying, suggesting that it may provide symptom relief in several GI diseases.